UA106721C2 - Сполуки азабіцикло[3.2.0]гепт-3-илу, спосіб їх одержання і фармацевтична композиція, яка їх містить (варіанти) - Google Patents

Сполуки азабіцикло[3.2.0]гепт-3-илу, спосіб їх одержання і фармацевтична композиція, яка їх містить (варіанти)

Info

Publication number
UA106721C2
UA106721C2 UAA201014568A UAA201014568A UA106721C2 UA 106721 C2 UA106721 C2 UA 106721C2 UA A201014568 A UAA201014568 A UA A201014568A UA A201014568 A UAA201014568 A UA A201014568A UA 106721 C2 UA106721 C2 UA 106721C2
Authority
UA
Ukraine
Prior art keywords
compounds
azabicyclo
hept
variants
preparation
Prior art date
Application number
UAA201014568A
Other languages
English (en)
Russian (ru)
Inventor
Касара Патрік
Шолє Ан-Марі
Дено Ален
Лєстаж Пьєр
Панайї Фанні
Original Assignee
Ле Лаборатуар Сервьє
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервьє filed Critical Ле Лаборатуар Сервьє
Publication of UA106721C2 publication Critical patent/UA106721C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Сполуки формули (І): EMBED ISISServer , (І) в якій: • ALK являє собою алкіленовий ланцюг, • W являє собою групу EMBED ISISServer , в якій R і R' є такими, як визначено в описі. Лікарські засоби.
UAA201014568A 2009-12-09 2010-12-06 Сполуки азабіцикло[3.2.0]гепт-3-илу, спосіб їх одержання і фармацевтична композиція, яка їх містить (варіанти) UA106721C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905957A FR2953514B1 (fr) 2009-12-09 2009-12-09 Nouveaux derives azabicyclo[3.2.0]hept-3-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
UA106721C2 true UA106721C2 (uk) 2014-10-10

Family

ID=42133738

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201014568A UA106721C2 (uk) 2009-12-09 2010-12-06 Сполуки азабіцикло[3.2.0]гепт-3-илу, спосіб їх одержання і фармацевтична композиція, яка їх містить (варіанти)

Country Status (44)

Country Link
US (1) US8008337B2 (uk)
EP (1) EP2332910B1 (uk)
JP (1) JP5511645B2 (uk)
KR (1) KR101292705B1 (uk)
CN (1) CN102127004B (uk)
AP (1) AP2755A (uk)
AR (1) AR079268A1 (uk)
AU (1) AU2010246426B2 (uk)
BR (1) BRPI1005270A2 (uk)
CA (1) CA2724151C (uk)
CL (1) CL2010001309A1 (uk)
CO (1) CO6280059A1 (uk)
CR (1) CR11811A (uk)
CU (1) CU23993B1 (uk)
CY (1) CY1113971T1 (uk)
DK (1) DK2332910T3 (uk)
EA (1) EA018971B1 (uk)
EC (1) ECSP10010649A (uk)
ES (1) ES2405206T3 (uk)
FR (1) FR2953514B1 (uk)
GE (1) GEP20135801B (uk)
HN (1) HN2010002593A (uk)
HR (1) HRP20130307T1 (uk)
IL (1) IL209463A (uk)
JO (1) JO2880B1 (uk)
MA (1) MA32444B1 (uk)
ME (1) ME01504B (uk)
MX (1) MX2010013093A (uk)
MY (1) MY150598A (uk)
NI (1) NI201000206A (uk)
NZ (1) NZ589763A (uk)
PE (1) PE20110542A1 (uk)
PL (1) PL2332910T3 (uk)
PT (1) PT2332910E (uk)
RS (1) RS52698B (uk)
SA (1) SA110320007B1 (uk)
SG (1) SG172543A1 (uk)
SI (1) SI2332910T1 (uk)
SV (1) SV2010003746A (uk)
TW (1) TWI419875B (uk)
UA (1) UA106721C2 (uk)
UY (1) UY33046A (uk)
WO (1) WO2011070250A1 (uk)
ZA (1) ZA201008651B (uk)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9300625B (sl) * 1993-12-02 2002-02-28 Basf Aktiengesellschaft N-substituirani derivati azabicikloheptana, njihova priprava in uporaba
DE4341402A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
RS52698B (en) 2013-08-30
CL2010001309A1 (es) 2012-01-13
CU23993B1 (es) 2014-04-24
MX2010013093A (es) 2011-06-14
TWI419875B (zh) 2013-12-21
JP5511645B2 (ja) 2014-06-04
ECSP10010649A (es) 2011-07-29
AP2755A (en) 2013-09-30
PE20110542A1 (es) 2011-08-18
JO2880B1 (en) 2015-03-15
HN2010002593A (es) 2013-03-18
SV2010003746A (es) 2011-03-15
JP2011121945A (ja) 2011-06-23
IL209463A (en) 2014-06-30
ES2405206T3 (es) 2013-05-30
US8008337B2 (en) 2011-08-30
AP2010005489A0 (en) 2010-12-31
CN102127004B (zh) 2013-10-23
TW201200498A (en) 2012-01-01
CO6280059A1 (es) 2011-05-20
FR2953514A1 (fr) 2011-06-10
AU2010246426A1 (en) 2011-06-23
PT2332910E (pt) 2013-02-26
EP2332910B1 (fr) 2013-01-30
WO2011070250A1 (fr) 2011-06-16
SA110320007B1 (ar) 2013-10-03
BRPI1005270A2 (pt) 2013-04-30
EA201001755A1 (ru) 2011-10-31
PL2332910T3 (pl) 2013-06-28
CA2724151A1 (fr) 2011-06-09
MY150598A (en) 2014-01-30
CY1113971T1 (el) 2016-07-27
EA018971B1 (ru) 2013-12-30
CU20100236A7 (es) 2011-11-15
GEP20135801B (en) 2013-04-10
SI2332910T1 (sl) 2013-05-31
UY33046A (es) 2011-05-31
MA32444B1 (fr) 2011-07-03
KR101292705B1 (ko) 2013-08-02
NZ589763A (en) 2012-05-25
US20110136886A1 (en) 2011-06-09
ZA201008651B (en) 2011-10-26
KR20110065384A (ko) 2011-06-15
SG172543A1 (en) 2011-07-28
ME01504B (me) 2014-04-20
CR11811A (es) 2011-02-04
IL209463A0 (en) 2011-02-28
DK2332910T3 (da) 2013-05-13
CA2724151C (fr) 2013-03-26
CN102127004A (zh) 2011-07-20
EP2332910A1 (fr) 2011-06-15
HRP20130307T1 (hr) 2013-04-30
NI201000206A (es) 2014-01-07
AR079268A1 (es) 2012-01-04
AU2010246426B2 (en) 2013-06-27
FR2953514B1 (fr) 2011-12-23

Similar Documents

Publication Publication Date Title
GEP20135963B (en) Pharmaceutical composition comprising linagliptin and sglt2 inhibitor; and usage thereof
MY149731A (en) Compounds
MX2011012122A (es) Derivados de tiofeno.
MY158438A (en) Antibodies against human angiopoietin 2
SG171649A1 (en) Dpp iv inhibitor formulations
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
MX2009013501A (es) Compuestos piperidinicos y sus usos.
UA98623C2 (uk) Сполуки діосметину, спосіб їх одержання і фармацевтична композиція, яка їх містить
WO2010049449A3 (en) Novel salts of sunitinib
UA95253C2 (uk) Сполуки аналога камптотецину, спосіб їх одержання і фармацевтична композиція, яка їх містить
MX2010009147A (es) Derivados de pirrolidinilo y usos de los mismos.
SG10201406846XA (en) Bisphosphonate compounds for treating bone metabolism disorders
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
GB0615105D0 (en) Novel compounds
PL1979321T3 (pl) Nowe pirydynyloaminoalkileno- i pirydynyloksyalkileno- cyklopropanoaminy, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
HK1147751A1 (en) Carbamoylglycine derivatives
UA93190C2 (uk) Сполуки нафталіну, спосіб їх одержання і фармацевтична композиція, яка їх містить
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
UA106721C2 (uk) Сполуки азабіцикло[3.2.0]гепт-3-илу, спосіб їх одержання і фармацевтична композиція, яка їх містить (варіанти)
MY144748A (en) Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them
GB0620619D0 (en) Novel compounds
UA105675C2 (uk) Бензодіазепіновий інгібітор бромодомену
UA102950C2 (uk) Азабіцикло[3.1.0]гекс-2-илові сполуки, спосіб їх одержання та фармацевтична композиція, що їх містить
UA93864C2 (uk) Сполуки нафталіну, спосіб їх одержання і фармацевтична композиція, яка містить їх